PMID: 9660996Jul 14, 1998Paper

Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems

Antimicrobial Agents and Chemotherapy
C ArdanuyL Martínez-Martínez

Abstract

Fifteen isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases (ESBLs) isolated during a nosocomial outbreak were studied. The strains belonged to the same clonal type, as shown by pulsed-field gel electrophoretic analysis of chromosomal DNA. All the isolates were resistant to extended-spectrum cephalosporins, aztreonam, gentamicin, and fluoroquinolones and were susceptible to carbapenems, tobramycin, netilmicin, and amikacin. None of the isolates expressed the OmpK36 porin. Eight isolates, for which the MICs of cefoxitin were > or = 64 micrograms/ml, showed a diminished level or no expression of a 35-kDa porin. The MICs of meropenem, cefotaxime, and cefpirome were three to eight times higher for porin-deficient isolates than for isolates expressing the 35-kDa porin, but the MICs of imipenem increased two times for porin-deficient isolates compared to those for isolates expressing the porin. This MIC increase reverted to a level similar to that for the parental strain when porin-deficient isolates were transformed with the gene coding for the K. pneumoniae porin OmpK36. It is concluded that the high level of resistance to cefoxitin and the increase in the MICs of meropenem, cefotaxime, and cefpirome for t...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Jun 1, 1991·Antimicrobial Agents and Chemotherapy·A RaimondiH Nikaido
Sep 1, 1991·Molecular Microbiology·D JeanteurF Pattus
Sep 1, 1991·Antimicrobial Agents and Chemotherapy·G A Jacoby, A A Medeiros
Jun 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P LegrandA Philippon
Nov 1, 1989·Antimicrobial Agents and Chemotherapy·H Nikaido
Dec 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J A van de KlundertS de Marie
Sep 1, 1993·Annals of Internal Medicine·K S MeyerJ J Rahal

❮ Previous
Next ❯

Citations

Nov 26, 2003·Antimicrobial Agents and Chemotherapy·Hesna YigitFred C Tenover
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group
Nov 20, 2018·FEMS Microbiology Reviews·José A Bengoechea, Joana Sa Pessoa
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Antonio Doménech-SánchezVicente Javier Benedí
Jun 27, 2009·Journal of Medical Microbiology·David LandmanJohn Quale
Jun 27, 2012·Antimicrobial Agents and Chemotherapy·Thierry NaasPatrice Nordmann
Jan 26, 2005·FEMS Microbiology Letters·Martina Skopková-ZarnayováCatherine Neuwirth
May 13, 2009·PloS One·Chloë E JamesJean-Marie Pagès
Jul 27, 2007·Revista Da Sociedade Brasileira De Medicina Tropical·Everardo Albuquerque MenezesFrancisco Afrânio Cunha
Aug 16, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Lucia PulzovaLubos Comor
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Sep 10, 2003·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Feng-Jui ChenHsiu-Jung Lo
Oct 15, 2005·Clinical Microbiology Reviews·David L Paterson, Robert A Bonomo
Feb 2, 2011·Antimicrobial Agents and Chemotherapy·Laura García-SuredaSebastián Albertí
Dec 17, 2015·Antimicrobial Agents and Chemotherapy·Kelli L TurnerTerri N Ellis
Mar 20, 2015·Clinical Microbiology Reviews·Xian-Zhi LiHiroshi Nikaido
Nov 26, 2020·Journal of Infection and Public Health·Sureka IndrajithSaravanan Muthupandian
Apr 2, 1999·Antimicrobial Agents and Chemotherapy·S Hernández-AllésS Albertí
Jul 21, 2006·Diagnostic Microbiology and Infectious Disease·Soo-Young KimKyungwon Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.